- Home
- BDTX
BDTX
Black Diamond Therapeutics Inc.
as 04-18-2025 1:31pm EST
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $15.60 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $7.66 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Black Diamond Therapeutics Inc. (BDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BIOTECH GROWTH N V | BDTX | 10% Owner | Mar 19 '25 | Sell | $2.07 | 5,784,292 | $11,997,749.13 | 7,517,839 |
Latest Black Diamond Therapeutics Inc. News
BDTX Breaking Stock News: Dive into BDTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Pharmaceutical Technology
a month ago
Servier and Black Diamond sign deal for solid tumours therapy
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Top Midday Gainers
MT Newswires
a month ago
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors
GlobeNewswire
a month ago
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
MT Newswires
a month ago
Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating
Associated Press Finance
a month ago
Black Diamond: Q4 Earnings Snapshot
Compare BDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDTX Black Diamond Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.